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Abstract
Background: The elderly population has been growing in most low- and middle-income countries (LMIC), and
depression is a common condition among these populations. The lack of integration between mental health and
primary healthcare services and the shortage of mental health specialists in the public health system contribute to
underdiagnosis and undertreatment of depression. One of the strategies to reduce this gap is task shifting and
collaborative care treatments. This study therefore aims to evaluate the effectiveness and cost-effectiveness of a
collaborative care psychosocial intervention to improve the clinical management of depression among elderly
people in poor neighbourhoods in Guarulhos, Brazil.
Methods: Two-arm, cluster randomised controlled trial with Basic Health Units as the clusters and a 1:1 allocation
ratio. Twenty Basic Health Units have been randomly selected and randomised to control or intervention arms. We
aim to recruit 1440 adults (72 per cluster) aged 60 years or over identified with depression (9-item Patient Health
Questionnaire (PHQ-9) score≥ 10). The control arm participants will receive an enhanced usual care, while the
intervention arm participants will receive an enhanced usual care and a 17-week psychosocial intervention programme
delivered at home by community health workers with the help of an application installed on tablet computers. The
primary outcome is the proportion with depression recovery (PHQ-9 < 10) at 8 months’ follow-up. We will also assess
the maintenance of any earlier clinical gains and the cost-effectiveness of the intervention at 12months.
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Discussion: This is the first randomised trial to investigate a collaborative care intervention to treat depression among
poor elderly in LMIC/Latin America. This is a major public health problem worldwide, but in these countries, there are
no locally tested, evidence-based interventions available to date.
Trial registration: International Standard Randomised Controlled Trial Number ISRCTN57805470. Registered on 25 April 2019
Keywords: Depression, Collaborative care, Elderly, Randomised controlled trial, Primary healthcare, Protocol, LMIC
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Introduction
Background and rationale {6a}
The rapid growth of the elderly population is a reality in
most low- and middle-income countries (LMIC). Brazil had
more than 30 million people aged over 60 years in 2017
(14% of the population, with 8% being women) [1, 2].
Depression is the leading cause of disability worldwide
[3] and among older adults is a common chronic
condition with a prevalence around 8% according to the
World Health Organization (WHO) [4]. A National
Health Survey-Brazil (2013) found a higher prevalence of
depression diagnosis in people aged between 60 and 64
years (11.1%) and 65 and 74 years (9.9%) compared with
the other age groups over 18 years (3.9–8.8%) [5, 6].
Moreover, a study with older adults living in poor neigh-
bourhoods in São Paulo, Brazil, found that 5% of this
population met the criteria for a depressive episode and
that identification of depression symptoms was low, with
less than 5% of those who met these criteria being diag-
nosed by primary care services [7].
The existing primary care model in Brazil, the Family
Health Strategy (FHS) framework, puts emphasis on
regular household visits to encourage prevention with the
central role played by community health workers (CHWs),
early identification of health problems and improved
adherence to ongoing treatments. However, mental health
care is still not adequately integrated into the primary care
services, and there is a scarcity of trained mental health
resources working in the public system [8]. Thus,
depression in later life is often unidentified and left
untreated despite the vast array of adverse social, economic
and health consequences [7, 9, 10].
One strategy proposed by the World Health Organization
in order to reduce this treatment gap and alleviate shortages
of mental health specialists is task shifting from physicians
to nurses or other non-medical providers such as CHWs
[11]. In the context of mental health care, task shifting can
reduce the workload on psychiatrists and clinical psycholo-
gists and increase the number of people receiving mental
health interventions delivered by trained non-specialists with
appropriate supervision [12, 13].
The most effective primary care treatments for
depression have used collaborative and stepped-care
models developed in high-income countries [14–17].
Given the socio-cultural and healthcare system differ-
ences, it is not appropriate to simply generalise from evi-
dence gathered from these studies. Thus, it is imperative
that local cost-effective solutions are developed to ad-
dress depression in LMIC.
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To date, several collaborative task-shifted programmes
have been tested in LMIC with good results, but none of
these studies was conducted with older adults [18–21].
For this reason, we conducted a pilot study to investigate
the acceptability and feasibility of a psychosocial collab-
orative care intervention to treat depression among
elderly people attending Unidades Básica de Saúde
(UBS) or Basic Health Units in São Paulo, Brazil [22,
23]. Based on the positive results of this pilot study, we
are proposing to conduct what we believe will be the
first task shifting, stepped-care and collaborative care
intervention aimed at treating late-life depression in
LMIC/Latin America.
Objectives {7}
This study aims to evaluate the effectiveness and cost-
effectiveness of a psychosocial intervention to improve
the clinical management of depression among elderly
people in poor neighbourhoods in Guarulhos, Brazil.
Trial design {8}
It is a parallel two-arm, cluster, superiority randomised
controlled trial with Basic Health Units as the clusters
and a 1:1 allocation ratio.
Methods: participants, interventions and
outcomes
Study setting {9}
The trial will be conducted in the city of Guarulhos,
situated in the metropolitan region of São Paulo city,
Brazil. The estimated population of Guarulhos in 2019
was 1.38 million, of whom 8.2% are aged over 60 years
[24]. Around 39% of the population of Guarulhos is
covered by total or partial private health insurance, not
totally dependent on the public health system [25].
There is a total of 69 UBSs across the city of
Guarulhos [26]. Of those 69 UBSs, 47 work as a Family
Health UBS that covers about 32% of the population
[27]. Half of them (24 UBSs) [26] have four or more
Family Health Teams (FHTs), which are multi-
professional teams providing comprehensive primary
care to the population who live in the catchment areas.
The other 22 UBSs follow the traditional Brazilian pri-
mary healthcare model, where most of the care is pro-
vided through appointments with physicians at the UBS
and the outreach activities are far less prominent [28].
Eligibility criteria {10}
Clusters
UBSs with professionals working exclusively on the
FHS model with at least four FHTs embedded within
each one.
Individuals who will perform the intervention
The CHW is a lay health professional who is part of the
FHT. CHWs often live in the same territory covered by
the UBS. Their main roles involve mapping a defined
area of the FHT where around 750 families live (called
micro-area), visiting these households monthly and giv-
ing advice on health promotion and disease prevention
for all residents of the households covered by their
micro-area [29]. All CHWs who are working in the se-
lected FHTs are eligible to participate in this study. The
UBS managers and FHT members will be responsible




1 Individuals 60 years or older registered with the
selected FHTs were eligible for screening
2 Individuals with a score of 10 or above, a known
threshold for depression, on screening with the 9-
item Patient Health Questionnaire (PHQ-9) [30]
Exclusion criteria:
1 Individuals whose partner (or another person who
lives in the same household) has already been
included in the study
2 Individuals identified with acute suicidal risk
3 Individuals with hearing or vision loss
4 Individuals unable to communicate (non-native
speaker, cognitive impairment or psychotic
symptoms)
5 Individuals unable to engage in the trial for the
period of 12 months (terminal illness, partner with
terminal illness, plans to move out to another area
or full-time working)
Who will take informed consent? {26a}
All individuals aged 60 years or older will be asked to
consent to participate and be audio recorded by the
research assistants (RAs) before both screening and
baseline assessments. If the screening interview is
conducted by telephone, only the verbal consent will be
recorded. When the screening is conducted face-to-face,
participants will be asked to sign an informed consent
form. Moreover, a new informed consent to enter in the
trial will be obtained at the baseline assessment.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
On the consent form, participants will be asked if they
agree to the use of their data should they choose to
withdraw from the trial. Participants will also be asked
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for permission for the research team to share relevant
data with people from the Universities taking part in the
research or from regulatory authorities, where relevant.
This trial does not involve collecting biological specimens
for storage.
Interventions
Explanation for the choice of comparators {6b}
The control arm participants will receive an enhanced
usual care, while the intervention arm participants will
receive both an enhanced usual care and a collaborative
care psychosocial intervention. The main component of
the intervention is a psychosocial programme delivered
at home by trained CHWs who have additional support




This comprises improved recognition of depression by
the research team (screening with the PHQ-9 to identify
depression) followed by usual care. The research team
will send a list with the names of the individuals in-
cluded in the study to UBS managers (in the control and
intervention arms). The research team will not interfere
with usual care—for instance, prescription of medica-
tions, CHW usual monthly home visits or access to fam-
ily doctors or mental health specialists.
Psychosocial intervention
The psychosocial intervention was designed to provide
care for depressed older adults registered with UBSs
within the FHS framework in Brazil. The intervention is
planned to last 17 weeks. Core principles of the
intervention are:
 Task shifting: the CHWs are the bond between the
FHT members and the community and are involved
in the care of chronic conditions. As they visit
homes routinely, they have been chosen to deliver
the psychosocial intervention
 Collaborative care: the CHWs will work
collaboratively with all other members from their
FHTs to deliver the intervention
 Stepped care: the intensity of care management is
tailored according to needs. Those who need more
receive more and vice versa. The FHT will decide if
the participant needs further support. The
participant will continue receiving the psychosocial
intervention in situations where he/she is referred to
see the family doctor or mental health specialist
The intervention will be delivered at home for several
reasons: older adults have difficulties travelling; an
intervention at home is likely to improve adherence; the
CHW visits homes regularly; and it provides an
opportunity to contact caregivers, if available.
The intervention is also based on:
(a) Measurement-based care—depression symptoms
are measured in all home sessions with the PHQ-9
instrument
(b) Psychoeducation—education about depression,
relapse prevention strategies and simple ways to
cope with depression symptoms and associated
problems
(c) Behavioural activation technique—educate about
the importance of engaging in pleasant or
meaningful activities, thus increasing positive
interactions with their environment
(d) Use of technology—the CHWs will deliver the
intervention with the support of an application
installed on tablets [22, 23]
The intervention is divided into initial (3 weeks) and
second (14 weeks) phases. The initial phase includes
three, weekly home meetings and is the same for all
participants. The goal of the programme’s initial phase is
to start psychoeducation—that is, what are the main
symptoms of depression, how participants can deal with
their problems associated with depression, and develop
simple strategies to cope with these problems. When the
initial phase is completed, the participant will have
access to either low- or high-intensity second phase regi-
mens. If the participant shows improvement during the
initial phase (PHQ-9 < 10 in both sessions 2 and 3), the
low-intensity treatment regimen will be offered with five
additional meetings (three every other week followed by
two monthly). If no improvement is shown (PHQ-9 ≥ 10
in session 2 and/or session 3), the participant will
proceed to the high-intensity regimen having eight add-
itional meetings (six weekly followed by two monthly).
Thus, regardless of the regimen, the intervention will
last around 17 weeks in total.
During the second phase, the participants will learn
about behavioural activation and relapse prevention
techniques, that is, how participants can identify that
symptoms are returning. The choice of behavioural
activation was due to the demonstrated feasibility and
efficacy of this technique for the treatment of depression
[31, 32] and its acceptability by participants and health
workers in our pilot study [22]. It is a simple technique
to apply and requires only a short period of professional
training [12, 33].
Multimedia material (24 short videos with animations)
were developed to be used as support material and to be
watched during the sessions. The contents are
introduced by an anchor and illustrated by animations.
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Language was adapted to be easily understood by
participants. To assist with potential vision problems, we
will be using tablets with a minimum screen size of 9 in.
(about 23 cm).
Before the intervention starts in each UBS, the 12
CHWs participating in the study will receive training to
conduct the intervention. Training will be conducted at
the UBS by a clinical supervisor and an information
technology specialist, during three group sessions of 6 h
each. During the period of the intervention, the CHWs
will also receive group supervision at the UBS by a
mental health specialist. The maximum number of
CHWs in each group supervision will be six. Initially,
the supervision will be weekly, and then fortnightly or
less frequently depending on the need of CHWs. A
standard operating procedure (SOP) was developed for
planning, managing and conducting the intervention.
Criteria for discontinuing or modifying allocated
interventions {11b}
Cluster level
At UBS or FHT request.
Individuals who will perform the intervention
At CHWs or UBS manager request.
Individual participants
Moving out of the catchment area of the UBS during the
intervention or participant request. In situations where
the participant moves to a neighbourhood close to the
UBS and can attend the remaining sessions at the UBS,
the intervention will not be discontinued.
Strategies to improve adherence to interventions {11c}
Participants will be attributed to the CHWs according to
the geographical area where each CHW works, but
whenever possible, the CHWs will also be able to choose
the participants they already know or they feel more
comfortable with. The application is interactive; during
each session, participants can choose from pre-defined
options of depression-related discussion topics. Thus, we
will be able to provide a more enjoyable experience for
all people involved, while at the same time retaining a
pragmatic approach since this is very likely how such an
intervention would be applied if adopted in the future.
The date and time of each appointment will be agreed
between the participant and the CHW. The home-based
intervention prevents the displacement of the partici-
pants and minimises barriers to access. The support of
an application to watch short videos will be important
for the understanding of the intervention’s content. Par-
ticipants will also receive a booklet with written informa-
tion about the intervention that can be used to write
down the planned activities to be performed between
the sessions and the next appointments with the CHW.
Relevant concomitant care permitted or prohibited
during the trial {11d}
Usual care delivered by the FHT and any other form of
health care received by the participant will continue
without any restrictions in both study arms, including
the prescription of antidepressant drugs and scheduling
of medical appointments.
Provisions for post-trial care {30}
Participants will continue to receive care from the FHTs
after the trial termination.
Outcomes {12}
Primary outcome
The primary outcome is the proportion with depression
recovery (PHQ-9 < 10) measured 8 months after the
inclusion in the study.
Secondary outcomes
The proportion with depression recovery (PHQ-9 < 10)
at 12 months will assess the maintenance of any earlier
gains. The following additional secondary measures will
be completed at 8 and 12 months and compared
between the two arms: European Quality of Life five-
dimensional questionnaire, Five-level version (EQ-5D-
5L) [34]; ICEpop CAPability measure for Older people
(ICECAP-O) [35]; Behavioural Activation for Depression
Scale—Short Form (BADS-SF) [36]; Generalized Anxiety
Disorder-7 (GAD-7) [37]; and stressful life events [38].
We will assess the cost-effectiveness of the intervention
at 12 months.
Participant timeline {13}
Participants will have the baseline interview no more
than 28 days after the screening. In the intervention arm,
participants will have their first intervention session
about 2 weeks after their baseline interview. Follow-up
data collection is scheduled to occur at two time points,
8 and 12 months after consenting into the trial, for both
intervention and control arms. The 8-month follow-up
will be conducted between 30 and 34 weeks, and the 12-
month follow-up between 50 and 54 weeks. The total
length of participant commitment is therefore up to 54
weeks. The timeline of the study and assessments are
given in Fig. 1.
Sample size {14}
A total sample size of 374 individuals would detect a 15
percentage point difference (25% versus 40%) in
recovery between the control and intervention arms at 8
months, with 85% power and 2-sided 5% significance
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level. A 15 percentage point difference in recovery rates
is considered clinically meaningful. It is also achievable
given the results of previous similar studies including
our pilot [14, 15, 18, 22, 39, 40]. We anticipate 15% attri-
tion, which is readily achievable according to the pilot
study, which yields a corrected total sample size of 440.
We plan to include four FHTs in each UBS, and there-
fore, the UBSs may need to be selected applying a prob-
ability proportionate to size procedure [41] depending
on the variation in size of the eligible UBSs (though in
the event we have needed to include all 24 UBSs that
met the inclusion criteria). All of the following estimates
are based on our primary care survey [42] and our pilot
study in São Paulo [22]. We expect that on average 10%
of the individuals registered with each UBS will be aged
60 years or older and the prevalence of older adults scor-
ing above nine on the PHQ-9 is 10% in this population.
On average, there are approximately 400 individuals in
the eligible age range and therefore 40 individuals poten-
tially eligible in each FHT, though this is likely to reduce
to 24 once other entry criteria are applied. Based on
pilot data, of these 24 eligible individuals, we expect that
at least 20 will consent to enter the trial. However, ex-
perience in the pilot indicates that each CHW is likely
to be able to manage a maximum of six participants at
any given time in the trial, which means we will only be
able to recruit 18 of these 24. Based on our previous
study [42] and the literature, an intra-cluster correlation
coefficient of 0.03 is reasonable for the binary PHQ-9 re-
covery outcome [43]. With four FHTs per UBS, this
leads to a cluster size of 72 with 18 participants from
each FHT; a design effect of 3.13 is therefore indicated.
This leads to a total inflated sample size of 1378 individ-
uals, which would require 19.14 clusters. With 20 clus-
ters (10 in each arm), we anticipate a total of 1440
participants, yielding a power of 86.5% for our target dif-
ference; equivalently, we would retain 85% power if the
attrition rose to 19%. Moreover, if the attrition in the
pilot (7%) were to be repeated in the main trial, we
would have a power of approximately 90% to detect the
target difference of 25% versus 40%.
Recruitment {15}
Clusters
Twenty UBSs (clusters) will participate in the study and
four UBS will be (randomly) selected as reserves. Within
each one of the 24 UBSs, four FHTs will be randomly
Fig. 1 Schedule of enrolment, interventions and assessments. PHQ-9, 9-item Patient Health Questionnaire; EQ-5D-5L, European Quality of Life
five-dimensional questionnaire, five-level version; ICECAP-O, ICEpop CAPability measure for Older people; GAD-7, Generalized Anxiety Disorder-7;
BADS-SF, Behavioural Activation for Depression Scale—Short Form; LSNS-6, Lubben Social Network Scale-6—LSNS-6; 3-item UCLA, 3-item
University of California, Los Angeles (UCLA) loneliness scale
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sampled. Thus, a total of 80 FHTs will participate in the
study.
Individuals who will perform the intervention
Within each of the sampled FHTs, selection of the
CHWs to be involved in the study (three per FHT and
hence 12 per UBS) will be decided by the UBS manager
and the FHT members, consistent with what would
happen in practice. A total of 120 CHWs will be
selected to conduct the intervention. Additional CHWs
will be trained to replace the selected CHWs for a short
time in case of annual leave, health issues or any other
situation where replacement is required. There is no
need to select CHWs in the control arm.
Participants
The Health Secretariat of Guarulhos provided to the
study investigators a list with names and contact
information of the individuals aged 59 years or older
registered with all FHT randomly selected to participate
in the study. The list, generated by the electronic health
system database (called e-SUS), will be entered into the
PROACTIVE database in a random order, to avoid con-
ducting the recruitment using the original sequence of
the names contained on the e-SUS. Recruitment of the
participants from this list of individuals from both arms
will be conducted in two phases (screening and baseline
assessments) and in two waves (in order not to over-
burden CHWs). Each wave will last for a period of 30
weeks, comprising five blocks of 6 weeks. During each
block, participants of two intervention and two control
UBSs will be recruited; the second wave will be a repeat
of the first. Participants in each wave will only be con-
tacted if they are 60 years old or over on the date of re-
cruitment. In each wave, we will recruit 720 participants
(360 in each study arm, a total of 36 participants per
UBS, and nine participants per FHT).
From the pilot study [22], we recruited 6% of the total
population of those at least 60 years of age. To achieve our
targets for this study, we need to assess 24,000 individuals,
and a sub-contracted company will conduct the screening,
baseline and follow-up assessments according to an agreed
and detailed protocol and contract. We decided to sub-
contract as the number of people who will be screened for
depression is large and exceeds the capacities of our team.
A SOP for data collection during the interviews has been
developed to help the RAs.
Screening assessment As information from e-SUS data-
base is not frequently updated, we will ask the UBS
managers and CHWs to pre-screen a list of around 150
names per FHT in order to identify individuals who we
will not be able to find (dead or moved to another area)
and those who present clinical exclusion criteria. We
will also ask the CHWs to update the individuals’ con-
tact information.
The RA from the sub-contracted company will follow
the random order of names on the list to contact indi-
viduals for screening. The contact will be by phone or
home visit, and there will be at least one contact attempt
through a home visit before excluding any individual
from the study.
Baseline assessment If the individual scores 10 or above
on the PHQ-9 (screening interview) and does not
present any exclusion criteria, he/she will be invited to
the baseline assessment. All baseline interviews will be
conducted by a home visit. If the screening interview is
conducted by phone, at the end of the interview, the RA
will schedule a home visit to conduct the baseline assess-
ment. If the screening is conducted by a home visit, the
researcher will proceed to the baseline assessment on
the same day of the screening whenever possible, after
obtaining the participant’s written consent to enter the
trial. In situations where the individual prefers to con-
tinue with the baseline interview on another day, the RA
will schedule a new home visit.
Soon after recruitment is completed in each UBS, the
study coordinator will send a list to UBS managers (both
study arms) with the names of all individuals from their
clinics who agreed to participate in the study. The UBS
manager will be advised by the study coordinator to
inform the relevant FHT members about the individuals
under their care who are participating in the study.
From this point, the FHTs will manage these individuals
with depression according to usual practice. In the
intervention arm, besides informing UBS managers
about the participants included in the study, the clinical
supervisor from each UBS will also receive a list with the
names of all study participants before assigning them to
the CHW who will conduct the psychosocial
intervention.
Assignment of interventions: allocation
Sequence generation {16a}
Clusters
UBSs will be identified, approached to participate and
then randomised at the beginning of the study. For
stratification, we will use the educational level (percentage
of individuals with no education or who had completed a
literacy programme for adults) collected through the e-
SUS database of the individuals 60 years or older regis-
tered with each UBS. Stratification will be into two sets of
UBSs (according to whether they are above or below the
median on this educational variable). Four UBSs will be
randomly selected as reserves (two from each stratum), in
case a UBS decides subsequently to not take part in the
study. Of those 20 remaining UBSs, 10 will be randomly
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allocated to each arm of the trial (five from each stratum).
Also, four FHTs within each UBS will be randomly se-
lected to be part of the study.
Concealment mechanism {16b}
Not applicable at the level of the individual participant
given the nature of this cluster randomised trial, though
the UBSs (clusters) will all be recruited before allocation
to the trial arm is conducted.
Implementation {16c}
The Bristol Randomised Trials Collaboration (through a
merger, now part of the Bristol Trials Centre), which is a
UK Clinical Research Collaboration fully registered
Clinical Trials Unit, will conduct the randomisation of
the UBSs and FHTs, by an individual (TJP) not involved
in the trial recruitment process at any stage. Allocation/
selection will therefore be conducted remotely by an
individual not involved in the recruitment and will be
conducted only after all UBSs have formally confirmed
their participation in the trial.
Assignment of interventions: blinding
Who will be blinded {17a}
Complete blinding of participants or CHWs to trial
allocation is impossible given the nature of this
intervention. To decrease the risk of observer bias at
follow-up, the two follow-up assessments will be made
by RAs who are not involved in the initial recruitment
or in delivering the intervention. We will rotate these
RAs so that unless it is unavoidable the same researcher
does not conduct any interview with the same partici-
pant more than once. We will also ensure that the pri-
mary data analysis is completed blind to trial allocation.
Procedure for unblinding if needed {17b}
Unblinding will occur only after the analysis of primary
endpoints has been completed, and likewise after as
many of the secondary outcomes are considered as is
feasible before unblinding becomes impossible to avoid.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Collection of trial data
Individual data will be gathered and stored electronically
in an information technology system developed for the
management of this study. Participants consenting to
the trial will be informed of this and receive an ‘ID
number’ when entering the study. All data will be linked
using ID codes to identify the person. A list of IDs will
be kept in a secure place with access only to the joint
principal investigators. Data will be captured via digital
recorders, tablets and on paper when necessary.
Screening, baseline and follow-up data will be collected
by a sub-contracted company using a software provided
by the research team, and all data will be stored in the
study server. The sub-contract with the company will
ensure that access and protection of the data is consist-
ent with Medical Research Council guidelines and Na-
tional Health Council (Conselho Nacional de Saúde—
Brazil) (Resolution 196/96-2012) regulations. A quality
control assessment of a sample of the audio recordings
will be conducted by an independent researcher trained
by the research team. The main aim of this quality con-
trol is to ensure that all procedures have been correctly
followed by the RAs and all information has been given
to the participants. The research team will also supervise
the work of this company using a web interface devel-
oped to follow live updates of the assessment’s status.
All data will be kept in a secured server at the
University of São Paulo. Digital files will be stored
anonymised in password-protected directories on secure
computers.
We will use data recorded routinely with the app
(number and duration of psychosocial treatment sessions,
other actions performed at the sessions) to assess the
fidelity with which the intervention was delivered. A
detailed record of all clinical data will be kept. We will
record the training time for all staff involved in the study.
Instruments
The three main instruments used in this study are the
PHQ-9 (at the screening and follow-up assessments), the
EQ-5D-5L and the ICECAP-O.
The PHQ-9 [30, 44] is a well-validated brief depression
measure extensively used in clinical research, including
Brazil [45], among other reasons because it is sensitive
to changes over time [44, 46]. Acute suicide risk will be
assessed with a standardised questionnaire whenever the
ninth question of the PHQ-9 is scored 1 or more.
The EQ-5D [34, 47] is a generic preference-based out-
come measure that provides a common metric for policy-
makers to compare the cost-effectiveness of treatment in
diverse clinical settings. The EQ-5D is sensitive to changes
in mental health outcomes in the literature [48, 49], and
the new five-level version was correlated with changes in
the PHQ-9 scores in the pilot study [22].
The ICECAP-O [35] measure will be used to assess
broader wellbeing/capability (for example, independence,
security) of participants. We have registered the intention
to use both EQ-5D and ICECAP-O instruments with the
developers of these instruments.
We will also collect information on participants’
sociodemographic profile, health condition, anxiety
symptoms (GAD-7) [37], social network (Lubben Social
Network Scale-6—LSNS-6 [50, 51]), stressful life events
[38], smoking habits, alcohol use (Alcohol Use Disorders
Identification Test-Consumption—AUDIT-C) [52],
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disability, behaviour activation (BADS-SF) [36], loneli-
ness (3-item University of California, Los Angeles
(UCLA) loneliness scale) [53], work loss productivity,
use of private care, need of care, use of medication for
chronic conditions, consultations with healthcare profes-
sionals and admission to hospital. The economic assess-
ment will also include resources used during the CHW
training and supervisory sessions and data collected
from medical records and the public health system data-
bases (consultations and procedures).
Plans to promote participant retention and complete
follow-up {18b}
We will inform participants from both arms about the
approximate date of the two follow-up interviews.
Follow-up assessments will ideally be conducted face-to-
face, but it can also be conducted by phone when neces-
sary. We decided to include a time ‘window’ to reflect
the logistical realities of the context and to maximise re-
sponse to follow-up. If any participant from either arm
is not contactable for the follow-up interview, we will
contact the neighbours and the UBS managers to con-
firm current contact details.
Data management {19}
The electronic data will be stored in our server, which
has several mechanisms to ensure that data remain
confidential and inaccessible to others than those with
access rights. The principal investigators will be
responsible for data security. All computers used in this
project will be password protected, and access to data
files archived will also be password protected. There will
be a database backup updated daily and stored in a
different secure server at the University of São Paulo
and mirrored on a server in Limerick, Ireland, where the
information technology platform has been developed.
The study will be compliant with the UK’s and Brazil’s
regulations on research data management. A summary
of the data management will be included in the
Informed Consent Form given to participants.
We will create a data dictionary, with detailed
information on labelling and codes, and describe data,
annotations and variables in such a way as to make
possible to use by authorised third parties.
Once data are entered to the main database, it will be
locked and no further changes are allowed to the
original version, albeit with (auditable) changes made in
subsequent versions following (usual) data checking
processes.
Confidentiality {27}
All data storage in Brazil will be compliant with the
National Commission of Ethics in Research (Comissão
Nacional de Ética em Pesquisa), Resolution 466/2012
security policies. All data kept in computers will be
anonymised. Paper records will be kept to a minimum
and stored in secure storage facilities. Any personally
identifiable paper record will be stored separately from
anonymised paper records. All electronic records will be
stored on password-protected servers. All data will be
encrypted to ensure its security. We will put in place
any required limitations on data sharing that serve to
safeguard the privacy of research participants.
The University of São Paulo has a modern network
infrastructure and clear procedures to ensure
confidentiality of the data. Parallel storage systems are
located at a different location and backed up regularly.
Access to data files is controlled by login and password
authentication. The data generated and collected
through this project will be maintained with the level of
security available.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
There will be no biological specimen collection for this
clinical trial.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Primary analysis
The analysis and presentation of data will be in
accordance with the Consolidated Standards of Reporting
Trials guidelines [54], with the primary comparative
analysis being conducted on an intention-to-treat basis
(including only those individuals with known primary out-
come and emphasis placed on confidence intervals for
between-arm comparisons). Descriptive statistics of demo-
graphic and clinical measures will be used to ascertain any
marked imbalance between the trial arms at baseline. The
primary comparative analysis will employ random-effects
multivariable logistic regression on the primary outcome
to obtain an odds ratio of recovery between the arms at 8
months after adjusting for baseline PHQ-9 scores, stratifi-
cation and cluster design.
Secondary analyses
Other secondary analyses will include (a) comparison of
the primary outcome measure at 12 months and using
the PHQ-9 score as a continuous variable at both
follow-up times (including the use of repeated measures
regression models), (b) repeating the analysis for the pri-
mary outcome adjusting for any observed imbalance
between arms of potential predictor variables at the level
of the individual and/or the UBS (introduction of the
latter would involve the use of suitable multi-level
models) and (c) similar analyses for secondary outcomes
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for participants at 8 and 12 months. In addition to the
adjustment for clustering by (allocated) UBS in the pri-
mary analyses, multi-level models will be employed to
investigate the extent to which the primary analyses
were affected by various clustering effects—UBSs, FHTs
and CHWs.
Economic analysis
The primary economic analysis will take a Brazilian
public health system perspective. Quality-adjusted life
years (QALYs) over the 12-month follow-up period will
be calculated based on EQ-5D-5L responses using the
most appropriate EQ-5D-5L value set available at the
time of the analysis. In the primary analysis, the incre-
mental costs and QALYs of the psychosocial interven-
tion will be combined to estimate the incremental net
monetary benefit of the intervention at a range of ‘will-
ingness-to-pay’ thresholds. We will also estimate cost-
effectiveness acceptability curves to illustrate the prob-
ability that the intervention is cost-effective at a range of
thresholds. In a secondary analysis, we will estimate the
incremental cost-effectiveness ratio of the psychosocial
intervention compared to enhanced usual care using the
primary clinical outcome measure (i.e. cost per patient
recovered at 8 months).
Interim analyses {21b}
In terms of the statistical and economic analyses of the
trial, we do not envisage conducting any between-arm
comparisons as interim analyses. The database will be
locked by the transaction manager after quality controls.
The only reason to check this database before complet-
ing the trial is when there is a major concern about the
health and/or wellbeing of a participant. However, this
would involve only the participant concerned, and this
information may need to be shared with others involved
in the safety of participants.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
Exploratory subgroup analyses will be undertaken to
investigate potential differential effects of the intervention
according to pre-specified characteristics of the partici-
pants. While the list of potential effect modifiers will be
finalised prior to publishing the Statistical Analysis Plan
for the trial, the current plan is to consider at least some
of the following: gender, age (as a continuous or grouped
variable), educational level, presence of co-morbid phys-
ical illnesses and severity of depression (the continuous
PHQ-9) at baseline. Such analyses will be interpreted cau-
tiously, partly because we do not have an overwhelming
single prior hypothesis for these analyses and partly be-
cause statistical power will be limited for the required
interaction effects within the relevant regression models.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Sensitivity analysis using multiple imputation models for
missing values will be conducted to investigate the
potential effects of missing data and attrition. Further
secondary analyses will compare individuals according to
the intervention they received, accounting for any
selection effects after random allocation using complier-
average causal effect methods employing instrumental
variables regression models. These analyses will first use
a binary definition of an ‘adequate dose’ of the interven-
tion, as follows: in the low-intensity group, a minimum
of 6 sessions; in the high-intensity group, a minimum of
7 sessions. We will also conduct these analyses accord-
ing to the number of sessions attended.
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
Summary information of the datasets will be published
in relevant research data repositories and directories.
Our data will be locked until our main hypothesis-based
analyses are completed and published or for 3 years after
completion of data collection (whichever is earlier), after
which the data will be accessible for external use. The
research team has interest in mutually sharing and pool-
ing metadata with other research groups. Data will not
be shared with any other source or used for any other
purpose other than those approved by the Ethics
Committees.
We plan to maximise the availability of research data
with as few restrictions as possible, ensure that data
should be released in a format that conforms to agreed
standards, especially where this allows interoperability
with other relevant datasets, require that all users of
data acknowledge the sources of their data and conform
with the terms and conditions under which they
accessed the original data, and put in place any required
limitations on data sharing that serve to safeguard the
privacy of research participants.
We will implement a data management and sharing
plan. This plan will specify the roles, responsibilities and
relationships of key persons involved in the research: the
applicant, sponsors and collaborators, research team
members, research participants and research institutions.
The joint principal investigators, in consultation with a
Data Access Committee, will be responsible to grant
access to the data, which will be in compliance with
sponsors’ regulations. There will be a form to fill to
request access to the data. The joint principal
investigators will review and approve any such requests.
Thus, study data will be made available to researchers
after written requests spelling out the specific aims and
plan of analysis. If there are conflicts of interest or
requests to use data for purposes other than those
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approved by the Ethics Committee, we will seek advice
from them to resolve any such disputes if they ever occur.
Data sharing will be in compliance with the principles
outlined in Good Practice Principles for Sharing
Individual Participant Data from Publicly Funded Clinical
Trials. External users will be bound by appropriate data
sharing agreements with the Ethical Committee and in
line with sponsors and funders’ policies.
Oversight and monitoring
Composition of the coordinating centre and Trial Steering
Committee {5d}
Coordinating centre
University of São Paulo, São Paulo, Brazil.
Trial Steering Committee (TSC)
The TSC will meet once a year and is composed of:
Independent chair Professor Simon Gilbody, Professor
of Psychological Medicine and Health Services Research,
University of York, UK.
Members Dr. Marcia Scazufca, Study PI—FAPESP-
Brazil, USP Medical School, University of São Paulo,
Brazil.
Professor Ricardo Araya, Study PI—MRC-UK,
Institute of Psychiatry, Psychology and Neuroscience,
King’s College London, UK.
Professor Tim Peters, Study Co-investigator, Bristol
Medical School, University of Bristol, UK.
Professor Roberto Lourenço, Director of the
Department of Geriatrics, Professor of Geriatrics,
Pontifical Catholic University of Rio de Janeiro, Brazil
(Independent member).
Rodrigo Fonseca Martins Leite, M.D., Lecturer,
Municipal University of São Caetano do Sul, Brazil
(Independent member).
Walter Freitas Junior, M.D., Director of the Division of
Health Education Management and Coordinator of the
Multi-professional Residency Committee—Escola SUS,
Guarulhos Health Secretariat, Brazil (Independent
member).
Paula Verônica Martini Maciel, D.D.D., Coordinator of
the Medical Residency Committee and Member of the
Technical Staff of Escola SUS, Guarulhos Secretary of
Health, Brazil (Independent member).
Composition of the Data Monitoring Committee, its role
and reporting structure {21a}
Data Monitoring Committee (DMC)
Independent chair Dr. Claudia de Souza Lopes,
Associate Professor, Institute of Social Medicine, Rio de
Janeiro State University, Brazil
Adverse event reporting and harms {22}
In this study, serious adverse event (SAE) data will be
collected—that is, any untoward medical occurrence that
is believed by the investigators to be causally related to
study intervention. SAEs can result in any of the
following: death, attempted suicide, life-threatening situ-
ations (that is, immediate risk of death) or significant
physical or emotional disability/incapacity. SAEs of indi-
viduals who discontinued participation will not be re-
ported. CHWs and sub-contracted RAs will be trained
to obtain SAE information from visits. The intervention
coordinator will be responsible for the completion of
SAE forms and contacting the principal investigator,
when necessary. Where appropriate, reports should be
forwarded promptly to the Ethics Committee of the USP
Medical School, with a copy to the DMC chair. A SOP
for SAE recording, management and reporting was also
developed to guide the team.
We do not think that this trial poses any considerable
risks to trial participants. The intervention to be
evaluated adds to existing usual care, and the trial does
not prevent family doctors or other FHT professionals
initiating or changing treatment for depression or any
other health problem. None of the components to be
tested is considered harmful.
The risk of suicide among depressed participants will
be assessed regularly, and participants at high risk at any
stage will receive immediate support from the sub-
contracted RA or CHW, something that does not occur
at present. CHWs and sub-contracted RAs will be
trained in assessing risk with a standardised protocol,
and CHWs will also receive ongoing supervision of their
cases. A safety plan has been developed to deal with
these emergencies and tested during our pilot study with
two participants at risk of suicide while receiving the
pilot psychosocial intervention. The safety plan was ap-
plied successfully by the CHWs in the pilot study. As
part of this safety plan, these participants were seen by
the family doctor for further assessment and subse-
quently managed by the FHT.
Frequency and plans for auditing trial conduct {23}
We will audit the recruitment (and retention) rates
across arms to investigate the extent of any differential
recruitment/retention and if any bias might accrue in
terms of depression scores. The DMC will be informed
of the findings of these checks.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
Any modifications on the study design, recruitment,
study procedures, intervention, data collection and data
analysis agreed between the research team, TSC and
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DMC will be communicated to the Ethical Committees
and funders. Guarulhos health system managers will also
be notified and need to agree with any modification
related to the daily functioning of their health units.
Protocol amendments will only be implemented after
appropriate approval has been received.
Dissemination plans {31a}
We expect to publish the results in internationally
competitive journals, something in which we have a good
track record [18, 19, 21, 55–57]. We will present the
project and results at local, regional and international
conferences in any of the relevant disciplinary fields.
Additional dissemination will be through the Centre for
Global Mental Health websites and programme of
extramural activities. We will engage King’s College
London’s press office and public engagement coordinator.
There will be media engagements and other dissemination
activities. Dissemination in Brazil will be assisted by the
press officers of the institutions involved. The core group
of investigators will convene 1 month before the end of
the study to discuss results and plans. In parallel, we will
organise dissemination meetings and workshops with
main stakeholders to discuss results and potential impact
of scaling up. We will arrange meetings of our experts
with our main stakeholders to assist us in the process of
enlisting their support and persuading them of the
importance of this and other similar future projects. We
have an intensive plan of dissemination of the results
involving policy-makers as well as potential funders/
donors in this field.
Discussion
The global burden of depression is rising, and the
elderly population presents an increased risk for
experiencing this disease. In many LMIC, the health
systems are unable to meet the mental health demand,
impacting negatively on the identification and treatment
of this population [58]. There is an urgent need for
feasible and affordable treatment programmes based in
primary care for later life depression.
A two-arm cluster, non-randomised controlled trial
pilot study [22] was conducted in two UBSs in São Paulo
to certify the feasibility of recruitment, assessments, ran-
domisation and acceptability of the proposed psycho-
social intervention. Twenty-five and 33 participants were
recruited for control and intervention arms, respectively,
and the 17-week psychosocial intervention was delivered
by CHWs and nurse assistants. The follow-up rates were
higher than 92% and both arms showed a lower PHQ-9
score mean around 30 weeks after inclusion, but there
was a substantially improvement in depression symp-
toms in the intervention UBS. Qualitative research also
indicated that the intervention was acceptable to both
participants and health professionals and the participants
enjoyed especially being seen at home regularly, the ac-
tivities and structure of the intervention, and the use of
technology and multimedia resources.
As far as we are aware of, this will become the first
large pragmatic trial to evaluate an intervention to
improve the management of depression among older
adults delivered by existing non-medical personnel in
LMIC/Latin America. As such, it will provide unique
and important information to Brazilian as well as other
policy-makers from countries experiencing similar prob-
lems. Potentially, this intervention could alleviate the
suffering of millions of people who currently receive lit-
tle or no help for their mental health problems.
Trial status
Protocol version 2.0 from 16 March 2020. The
recruitment of the first wave started on 23 May 2019
and of the second wave on 20 January 2020. Since 12
March 2020, the recruitment of new participants is
paused and the psychosocial intervention conducted by
the CHWs has been stopped due to the emergence of
the COVID-19 pandemic. The follow-up assessments
are being conducted by phone. We have plans to restart
the second wave when it is safe for everyone involved. If
the COVID-19 pandemic does not subside and therefore
does not allow the continuation of the RCT as described
in this protocol, we will discuss amendments and follow
appropriate approval from the relevant parties.
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